MDRNA to File Bladder Cancer IND by Year End, Eyes Two Big Pharma Deals in ’10
MDRNA’s top executive this week confirmed that the company has moved its bladder cancer program to the head of its pipeline, and that it would yield an investigational new drug application filing — the firm’s first — in the fourth quarter.
Read more on GenomeWeb News